Merck & Co., Inc. stock: Undervalued by 39% despite strong gains?

Merck & Co., Inc. shares have surged 56% over the past year, yet a DCF model suggests they're still trading at a 39% discount to intrinsic value. For investors eyeing pharma giants with robust pipelines, this could signal a compelling opportunity across U.S., European, and global markets. ISIN: US58933Y1055

You're eyeing Merck & Co., Inc. (NYSE: MRK, ISIN: US58933Y1055) because its stock has delivered impressive returns, but you're wondering if there's still upside left. After climbing 55.8% over the last year, 15.7% year-to-date, and showing recent gains of 5.2% in 30 days, the shares trade around recent levels that prompt valuation questions. A discounted cash flow analysis points to the stock being undervalued by about 38.7%, estimating an intrinsic value near $200 per share versus the current price around $123, making it a name worth your close attention right now.

As of: 09.04.2026

By Elena Harper, Senior Pharma Equity Analyst: Merck & Co., Inc. stands as a pharmaceutical powerhouse, driving innovation in oncology and vaccines amid evolving global healthcare demands.

Merck's Core Business: A Pharma Powerhouse You Can Rely On

Merck & Co., Inc., listed on the NYSE under ticker MRK in USD, focuses on discovering, developing, and delivering innovative health solutions globally. You know the company best for blockbuster drugs like Keytruda, its PD-1 inhibitor leading the oncology space, alongside vaccines such as Gardasil for HPV prevention. These products form the backbone of Merck's revenue, with oncology alone driving a significant portion of sales as demand for cancer treatments grows worldwide.

The business model emphasizes a robust R&D pipeline, strategic partnerships, and acquisitions to fuel growth. Whether you're investing from the U.S., Europe, or elsewhere, Merck's global footprint means its performance ties directly to international healthcare trends. This setup positions the company to capitalize on aging populations and rising chronic disease prevalence, key drivers you should track in your portfolio.

Recent performance underscores this strength: the stock notched 1.9% gains over the past week amid broader market rotations into defensive sectors like pharma. For you as an investor, this stability offers a hedge against volatility in tech or cyclicals, but it also raises the question of whether the heavy lifting on price appreciation is done.

Valuation Snapshot: Why Merck Looks Like a Bargain

At a forward P/E of 16.7x, Merck trades in line with the pharmaceuticals industry average of 16.5x but below peers at 25.1x, suggesting relative value. Simply Wall St's fair ratio estimate sits at 28.2x, factoring in growth prospects, margins, and risks, which implies the market may undervalue Merck's earnings power. You can see why investors are circling: despite strong returns, the DCF model flags a 38.7% discount to fair value.

This isn't just numbers on a screen—it's about Merck's pipeline delivering beyond expectations. Keytruda's dominance, protected by patents into the next decade, supports sustained cash flows. If you're building long-term wealth, this combination of proven products and undervaluation could make MRK a core holding, especially as global drug spending climbs.

Compare this to broader market multiples, and Merck stands out. While tech stocks chase growth at 30x or higher, pharma like MRK offers defensive earnings at a discount. Keep an eye on quarterly updates; any pipeline wins could close that valuation gap quickly.

Market Position and Growth Drivers

Merck holds a top-tier spot in oncology, immunology, and vaccines, competing with the likes of Pfizer, Bristol Myers Squibb, and Roche. Keytruda isn't just a revenue engine—it's the world's top-selling cancer drug, with sales growth outpacing the market. Add in animal health via the Organon spin-off legacy and new ventures in cardiometabolics, and you've got diversification you can bank on.

For global investors, Merck's exposure to emerging markets adds tailwinds. Europe benefits from its leadership in immuno-oncology, while U.S. Medicare dynamics influence pricing power. Watch how the company navigates biosimilar competition; successful defense here sustains premiums and margins.

Pipeline catalysts loom large: next-gen vaccines and combo therapies could extend growth runs. If you're allocating to healthcare, Merck's balance of current earnings and future bets makes it relevant whether markets rally or retreat.

Analyst Views: What Wall Street Sees for MRK

Analysts largely view Merck as a hold, with a consensus leaning toward maintaining positions rather than aggressive buying or selling. Out of recent coverage, ratings split with holds dominating, reflecting caution on near-term headwinds balanced by long-term pipeline strength. Firms highlight Keytruda's patent life and R&D momentum as positives, though some note valuation pressures after recent gains.

The average price target sits around levels implying modest upside from current trading, with a range spanning conservative to optimistic outlooks. This consensus underscores Merck's stability—suitable for you if seeking income via dividends alongside growth. Reputable houses emphasize capital allocation discipline, including buybacks and dividends, as supportive factors.

For U.S. and European investors, these views align with sector rotations favoring quality pharma. Track rating changes; upgrades on trial data could shift sentiment swiftly. Overall, analysts see MRK as a steady compounder, not a moonshot.

Risks and What to Watch Next

No stock is without hurdles, and for Merck, patent cliffs on blockbusters like Keytruda top the list. As exclusivity wanes post-2028, biosimilars could erode pricing power, squeezing margins if pipeline successors falter. You need to monitor clinical trial outcomes closely—delays or failures here amplify downside.

Regulatory shifts, like U.S. drug pricing reforms or EU tenders, pose ongoing threats. Supply chain issues in vaccines or raw materials could disrupt too. Globally, currency fluctuations impact reported results, a factor for non-U.S. investors.

Yet Merck mitigates via diversification: animal health and new modalities like ADCs provide buffers. Watch earnings for guidance updates, M&A activity, and dividend hikes—these signal confidence. If you're risk-averse, pair MRK with broader ETFs; for growth chasers, it's a pipeline play.

Investor Takeaway: Is Now the Time for You?

Should you buy Merck stock now? If undervaluation per DCF appeals and you favor defensive growth, yes—especially at current multiples versus peers. Its dividend yield, pipeline depth, and global reach suit U.S., European, and international portfolios building wealth steadily.

What matters most? Pipeline execution and patent strategies amid sector pricing battles. Relevance now ties to market rotations into healthcare amid economic uncertainty. Watch Q2 earnings, FDA nods, and competitor moves next.

Merck isn't flashy, but for patient investors, it compounds reliably. Balance it in your allocation, and stay vigilant on risks. This positions you to capture upside while managing exposures.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.